REG - Genus - Non-Executive Director Appointment

GenusAnnouncement

12/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231212:nRSL3988Wa&default-theme=true

RNS Number : 3988W  Genus PLC  12 December 2023

For Immediate Release

12 December 2023

Genus plc

("Genus" or the "Group")

Board Change: Non-Executive Director Appointment

 

Genus (LSE: GNS), a leading global animal genetics company, is pleased to
announce the appointment of Dr Ralph Heuser to the Board as a Non-Executive
Director, with effect from 1 January 2024.

Dr Heuser has had extensive experience in animal healthcare businesses
globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a
PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and
more recently in global leadership roles at Elanco Animal Health, including as
Vice President for Asia Pacific, Europe and International Commercial
Operations.  Dr Heuser has a PhD in Agricultural Economics from the
University of Bonn, Germany and is currently a Senior Advisor with Stonehaven
Consulting (SC Group) AG.

Dr Heuser brings widespread global experience in operations, commercial
excellence, integration and the animal health industry generally, and his
appointment follows an extensive search process using an external search
agency.

Commenting on the appointment, Iain Ferguson, Chair of Genus, said:

"We are delighted to welcome Ralph to the Board. Ralph brings invaluable
experience and knowledge of commercial strategy and operations in agricultural
and animal health businesses across many global markets, which will allow the
Board to maintain this area of expertise following the recent retirement of
Lykele Van Der Broek from our Board.  I would like to thank Lykele for his
significant contributions to Genus over the last nine years and wish him every
success for the future."

For further information please contact:

Genus plc            Tel: +44 (0)1256 345 970

Iain Ferguson, Chair

Jorgen Kokke, Chief Executive Officer

Buchanan            Tel: +44 (0)207 466 5000

Charles Ryland; Sophie Wills; Toto Berger; Verity Parker

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Ralph Heuser will be disclosed in full
in the Company's 2024 Directors' Remuneration Report.  Any such terms will be
consistent with the Company's approved Directors' Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 9.6.11R.   There
are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) -
(6). The person responsible for making this announcement on behalf of the
Group is Dan Hartley (General Counsel and Company Secretary).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXAFFDLDFFA